Clinica De Oftalmologia De Cordoba S.L.

The clinic’s research program targets major eye diseases such as neovascular and atrophic macular degeneration, focusing on innovative treatments that aim to preserve or improve vision.

• Evaluation of a Port Delivery System with ranibizumab for long‑term management of wet AMD.
• Assessment of RGX‑314 gene therapy as a novel approach for neovascular disease.
• Combination therapy using OPT‑302 with ranibizumab to enhance efficacy in neovascular AMD.
• Comparison of faricimab versus standard anti‑VEGF agents.
• Investigation of ONL1204 to slow progression of geographic atrophy.
• Study of cenegermin ophthalmic solution for healing persistent corneal epithelial defects.

Clinica De Oftalmologia De Cordoba S.L. provides a dedicated environment for advancing ocular therapeutics.

Research at the site also addresses disorders of the immune system affecting the orbit, particularly Thyroid Eye Disease and related Graves’ ophthalmopathy.

• Safety and efficacy of varying teprotumumab treatment durations in active TED.
• Evaluation of the IV biologic LASN01 for reducing inflammation and proptosis.
• Subcutaneous dosing studies of VRDN‑003 in both active and chronic TED.
• Infusion study of VRDN‑001 assessing long‑term outcomes in chronic disease.
• Phase evaluation of efgartigimod PH20 for immune‑mediated eye involvement.
• Dose‑ranging trial of TOUR006 targeting proptosis reduction.
• Comparison of K1‑70 versus placebo for exophthalmos improvement.

These studies aim to refine immunomodulatory strategies and improve quality of life for patients with orbital autoimmune conditions.

The institution explores fundamental ocular processes, employing advanced delivery platforms and monitoring visual function to enhance therapeutic outcomes.

• Long‑term safety monitoring of intravitreal injections and their impact on visual acuity stability.
• Pharmacokinetic profiling of sustained‑release devices for continuous drug exposure.
• Investigation of ocular surface healing dynamics using cenegermin in corneal defects.
• Assessment of physiological responses to combined anti‑VEGF regimens.

By linking physiological insights with clinical testing, the site advances both basic and translational ophthalmology.